Spin-off of IFCA (CSIC–UC) · Santander

Real-time in vivo dosimetry for high-dose-rate brachytherapy

We are developing a silicon carbide detector system that checks, while the treatment is running, that the dose delivered to the patient matches the dose that was planned.

TOP101 Spain Up Nation 2026UCem Award 2025
Particle Care Technologies symbol

The problem

A high dose, delivered in minutes, that nobody measures

~500,000 procedures / year

A precise, efficient treatment

HDR brachytherapy places a radioactive source inside the body through catheters. It treats prostate, cervical, breast and other cancers with a steep dose gradient that spares healthy tissue.

Many manual steps

Errors cannot be undone

Needles and catheters are placed by hand. A misplaced dose can reach the urethra, rectum or bladder, and the whole treatment is over in minutes, before anyone can react.

IAEA · ICRP

No routine verification

International bodies recommend in vivo dosimetry, and France and the UK already require it in external radiotherapy. In brachytherapy there is still no robust real-time solution.

Our approach

Silicon carbide detectors built for the inside of the body

Our sensor is based on silicon carbide (SiC) diodes, a semiconductor that withstands very high radiation doses and keeps a stable response at body temperature. Together with dedicated readout electronics, it measures the dose during the irradiation itself.

The technology comes from research at the Institute of Physics of Cantabria and has been characterised with a real 192Ir source in the brachytherapy suite of Hospital Universitario Marqués de Valdecilla.

  • >1,000s Gy
    Long service lifeRadiation-hard sensor, far beyond the ~200 Gy of current MOSFET dosimeters. No costly consumable.
  • 37 °C
    Thermally stableNo temperature compensation needed inside the patient.
  • Real time
    Flags errors as they happenDetects a deviation while the treatment can still be stopped.
  • Plug-in
    Fits the clinical workflowDesigned to integrate with existing equipment and protocols.
In vivo dosimetry technologies for HDR brachytherapy
TechnologyService lifeReal-time readingTemperature independenceCost / handling
4H-SiC · Particle CareVery long (>1,000s Gy)YesVery highLow / very flexible
MOSFETShort (~200 Gy)NoMedium–lowMedium / consumable
Optical fibre + scintillatorMediumYesLowMedium / complex
TLDMediumNoMediumLow / slow readout

Built for manufacturers

A verification layer for the next generation of afterloaders

We work business-to-business. Our goal is to license the technology to brachytherapy equipment manufacturers, so they can offer integrated, real-time dose verification with their systems, and to support that integration over the product's life.

72%HDR share of the global brachytherapy market (2025)
7.4%Expected annual market growth, 2026–2033
2031Target date for CE marking under the EU MDR

Milestones so far

Recognition and validation

2026TOP101 Spain Up NationSelected among Spain's 101 best emerging companies (ENISA & Foro ADR).
2026Favourable patentability reportIndependent assessment of novelty and inventive step.
2025UCem Award22nd University of Cantabria entrepreneurship award.
INNVAL 23/18Ethics approval at HUMVFavourable opinion of the hospital's ethics committee.